A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction

Clinical features and outcomes in the novel phenotype heart failure with mid‐range ejection fraction [HFmrEF, ejection fraction (EF) 40–49%] were compared with heart failure with reduced EF (HFrEF, EF <40%) and preserved EF (HFpEF, EF ≥50%).

[1]  M. de Antonio,et al.  Recovered heart failure with reduced ejection fraction and outcomes: a prospective study , 2017, European journal of heart failure.

[2]  R. Wachter,et al.  Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.

[3]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[4]  G. Aurigemma,et al.  Diastolic heart failure , 2004 .

[5]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[6]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[7]  C. Yancy,et al.  Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. , 2016, JACC. Heart failure.

[8]  C. O'connor,et al.  Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. , 2005, Journal of the American College of Cardiology.

[9]  L. Lund,et al.  Use of evidence‐based therapy and survival in heart failure in Sweden 2003–2012 , 2016, European journal of heart failure.

[10]  K. Tanabe,et al.  Effects of β-blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction. , 2016, International journal of cardiology.

[11]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[12]  L. Lund,et al.  Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of ≥50% , 2015, Circulation. Heart failure.

[13]  L. Friberg,et al.  Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. , 2014, JAMA.

[14]  J. Gore,et al.  Magnitude of and Prognostic Factors Associated With 1‐Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings , 2015, Journal of the American Heart Association.

[15]  D. McManus,et al.  Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. , 2014, The American journal of cardiology.

[16]  G. Aurigemma,et al.  Clinical practice. Diastolic heart failure. , 2004, The New England journal of medicine.

[17]  D. Burkhoff,et al.  Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%. , 2009, The American journal of cardiology.

[18]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[19]  J. Gardin,et al.  Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study , 2002, Annals of Internal Medicine.

[20]  C. Lam,et al.  Understanding Heart Failure With Mid-Range Ejection Fraction. , 2016, JACC. Heart failure.

[21]  U. Dahlström,et al.  Heart failure registry: a valuable tool for improving the management of patients with heart failure , 2010, European journal of heart failure.

[22]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[23]  Deepak L. Bhatt,et al.  Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. , 2014, American heart journal.

[24]  V. Roger,et al.  Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study. , 2013, American journal of epidemiology.

[25]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[26]  L. Lund,et al.  Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. , 2015, European heart journal.

[27]  C. Lam,et al.  The middle child in heart failure: heart failure with mid‐range ejection fraction (40–50%) , 2014, European journal of heart failure.

[28]  L. Lund,et al.  Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. , 2012, JAMA.

[29]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[30]  L. Lund,et al.  Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid‐range, and reduced ejection fraction , 2017, European journal of heart failure.

[31]  Karl Swedberg,et al.  Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.

[32]  L. Lund,et al.  Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study , 2017, European journal of heart failure.